Metabolic Dysfunction as a Rising Barrier to HBV Elimination

ABSTRACT About one‐third of patients with chronic hepatitis B (CHB) have hepatic steatosis, and cardiometabolic risk factors are increasingly prevalent. This review examines what metabolic dysfunction does to the measurements on which the elimination cascade depends, from prevention through diagnosis, treatment eligibility, on‐treatment risk control, and functional cure to postcure surveillance. Metabolic dysfunction lowers the response to adult vaccination, enters three of the four routes to treatment eligibility in the World Health Organization criteria, contributes to the hepatocellular carcinoma risk that persists during antiviral therapy, and is absent from most risk scores and surveillance rules used before and after hepatitis B surface antigen loss. Its two components diverge: hepatic steatosis and cardiometabolic burden appear to additively increase the probability of hepatitis B surface antigen loss, but act in opposite directions on cirrhosis, hepatocellular carcinoma, and mortality. Assessing and correcting metabolic dysfunction as part of CHB care, and including patients with CHB in trials of metabolic therapy, would allow success to be defined by liver outcomes rather than by the virus alone.

Authors

Institutions

Publication Details

Journal
Journal of Gastroenterology and Hepatology
Published
2026-11-13
DOI
https://doi.org/10.1111/jgh.70879
Primary Topic
Hepatitis B Virus Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Metabolic Dysfunction as a Rising Barrier to HBV Elimination

Chun‐Jen Liu, Shang‐Chin Huang
Journal of Gastroenterology and Hepatology
Hepatitis B Virus Studies
article

Metabolic Dysfunction as a Rising Barrier to HBV Elimination

Chun‐Jen Liu, Shang‐Chin Huang
article en

Abstract

ABSTRACT About one‐third of patients with chronic hepatitis B (CHB) have hepatic steatosis, and cardiometabolic risk factors are increasingly prevalent. This review examines what metabolic dysfunction does to the measurements on which the elimination cascade depends, from prevention through diagnosis, treatment eligibility, on‐treatment risk control, and functional cure to postcure surveillance. Metabolic dysfunction lowers the response to adult vaccination, enters three of the four routes to treatment eligibility in the World Health Organization criteria, contributes to the hepatocellular carcinoma risk that persists during antiviral therapy, and is absent from most risk scores and surveillance rules used before and after hepatitis B surface antigen loss. Its two components diverge: hepatic steatosis and cardiometabolic burden appear to additively increase the probability of hepatitis B surface antigen loss, but act in opposite directions on cirrhosis, hepatocellular carcinoma, and mortality. Assessing and correcting metabolic dysfunction as part of CHB care, and including patients with CHB in trials of metabolic therapy, would allow success to be defined by liver outcomes rather than by the virus alone.

Journal of Gastroenterology and Hepatology
National Taiwan University (TW), National Taiwan University Hospital (TW)
Hepatitis B Virus Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon